name,url,associated_proteins,associated_drugs
Transcriptional activation of mitochondrial biogenesis,,p(HGNC:IDH2),
Citric acid cycle (TCA cycle),,p(HGNC:IDH2),
Mitochondrial protein degradation,,p(HGNC:IDH2),
Maturation of TCA enzymes and regulation of TCA cycle,,p(HGNC:IDH2),
PIP3 activates AKT signaling,,p(HGNC:FLT3); p(HGNC:KIT); p(HGNC:PDGFRB); p(HGNC:PDGFRA),
Downstream signal transduction,,p(HGNC:PDGFRB); p(HGNC:PDGFRA),
Signaling by PDGF,,p(HGNC:PDGFRB); p(HGNC:PDGFRA),
Constitutive Signaling by Aberrant PI3K in Cancer,,p(HGNC:FLT3); p(HGNC:KIT); p(HGNC:PDGFRB); p(HGNC:PDGFRA),
RAF/MAP kinase cascade,,p(HGNC:FLT3); p(HGNC:KIT); p(HGNC:PDGFRB); p(HGNC:RET); p(HGNC:CSF2RA); p(HGNC:PDGFRA); p(HGNC:JAK2),
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",,p(HGNC:FLT3); p(HGNC:KIT); p(HGNC:PDGFRB); p(HGNC:PDGFRA),
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,,p(HGNC:CD33),
Neutrophil degranulation,,p(HGNC:IDH1); p(HGNC:PRKCD); p(HGNC:CD33),
PI3K Cascade,,p(HGNC:FLT3),
FLT3 Signaling,,p(HGNC:FLT3),
STAT5 Activation,,p(HGNC:FLT3),
FLT3 mutants bind TKIs,,p(HGNC:FLT3),
STAT5 activation downstream of FLT3 ITD mutants,,p(HGNC:FLT3),
KW2449-resistant FLT3 mutants,,p(HGNC:FLT3),
semaxanib-resistant FLT3 mutants,,p(HGNC:FLT3),
crenolanib-resistant FLT3 mutants,,p(HGNC:FLT3),
gilteritinib-resistant FLT3 mutants,,p(HGNC:FLT3),
lestaurtinib-resistant FLT3 mutants,,p(HGNC:FLT3),
midostaurin-resistant FLT3 mutants,,p(HGNC:FLT3),
pexidartinib-resistant FLT3 mutants,,p(HGNC:FLT3),
ponatinib-resistant FLT3 mutants,,p(HGNC:FLT3),
quizartinib-resistant FLT3 mutants,,p(HGNC:FLT3),
sorafenib-resistant FLT3 mutants,,p(HGNC:FLT3),
sunitinib-resistant FLT3 mutants,,p(HGNC:FLT3),
tandutinib-resistant FLT3 mutants,,p(HGNC:FLT3),
linifanib-resistant FLT3 mutants,,p(HGNC:FLT3),
tamatinib-resistant FLT3 mutants,,p(HGNC:FLT3),
Signaling by FLT3 ITD and TKD mutants,,p(HGNC:FLT3),
Negative regulation of FLT3,,p(HGNC:FLT3),
FLT3 signaling through SRC family kinases,,p(HGNC:FLT3),
FLT3 signaling by CBL mutants,,p(HGNC:FLT3),
Regulation of actin dynamics for phagocytic cup formation,,p(HGNC:ABL1),
Role of ABL in ROBO-SLIT signaling,,p(HGNC:ABL1),
Myogenesis,,p(HGNC:ABL1),
RHO GTPases Activate WASPs and WAVEs,,p(HGNC:ABL1),
HDR through Single Strand Annealing (SSA),,p(HGNC:ABL1),
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,,p(HGNC:ABL1); p(HGNC:TP53),
Cyclin D associated events in G1,,p(HGNC:ABL1); p(HGNC:JAK2),
RUNX1 regulates transcription of genes involved in differentiation of HSCs,,p(HGNC:ABL1),
RUNX2 regulates osteoblast differentiation,,p(HGNC:ABL1),
FCGR3A-mediated phagocytosis,,p(HGNC:ABL1),
Factors involved in megakaryocyte development and platelet production,,p(HGNC:ABL1); p(HGNC:TP53); p(HGNC:JAK2),
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,,p(HGNC:ABL1),
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",,p(HGNC:ABL1),
Apoptotic cleavage of cellular proteins,,p(HGNC:PRKCD); p(HGNC:PRKCQ),
Calmodulin induced events,,p(HGNC:PRKCD); p(HGNC:PRKCA),
Effects of PIP2 hydrolysis,,p(HGNC:PRKCD); p(HGNC:PRKCE); p(HGNC:PRKCH); p(HGNC:PRKCQ),
SHC1 events in ERBB2 signaling,,p(HGNC:PRKCD); p(HGNC:PRKCE); p(HGNC:PRKCA),
DAG and IP3 signaling,,p(HGNC:PRKCD); p(HGNC:PRKCE),
Role of phospholipids in phagocytosis,,p(HGNC:PRKCD); p(HGNC:PRKCE),
G alpha (z) signalling events,,p(HGNC:PRKCD); p(HGNC:PRKCE); p(HGNC:PRKCH); p(HGNC:PRKCQ); p(HGNC:PRKCA),
HuR (ELAVL1) binds and stabilizes mRNA,,p(HGNC:PRKCD); p(HGNC:PRKCA),
VEGFR2 mediated cell proliferation,,p(HGNC:KDR); p(HGNC:PRKCD); p(HGNC:PRKCA),
CLEC7A (Dectin-1) signaling,,p(HGNC:PRKCD),
RHO GTPases Activate NADPH Oxidases,,p(HGNC:PRKCD); p(HGNC:PRKCA),
Interferon gamma signaling,,p(HGNC:JAK2); p(HGNC:PRKCD),
KEAP1-NFE2L2 pathway,,p(HGNC:PRKCD),
Inhibition of replication initiation of damaged DNA by RB1/E2F1,,p(HGNC:POLA1),
Polymerase switching on the C-strand of the telomere,,p(HGNC:POLA1),
Telomere C-strand synthesis initiation,,p(HGNC:POLA1),
DNA replication initiation,,p(HGNC:POLA1),
Activation of the pre-replicative complex,,p(HGNC:POLA1),
Polymerase switching,,p(HGNC:POLA1),
Removal of the Flap Intermediate,,p(HGNC:POLA1),
Processive synthesis on the lagging strand,,p(HGNC:POLA1),
G1/S-Specific Transcription,,p(HGNC:POLA1),
Defective pyroptosis,,p(HGNC:POLA1); p(HGNC:DNMT3A); p(HGNC:DNMT1),
Nuclear Receptor transcription pathway,,p(HGNC:RARG); p(HGNC:RARA); p(HGNC:RARB),
Signaling by Retinoic Acid,,p(HGNC:RARG); p(HGNC:RARA); p(HGNC:RARB),
Activation of anterior HOX genes in hindbrain development during early embryogenesis,,p(HGNC:RARG); p(HGNC:RARA); p(HGNC:RARB),
Activation of NOXA and translocation to mitochondria,,p(HGNC:TP53),
Activation of PUMA and translocation to mitochondria,,p(HGNC:TP53),
Pre-NOTCH Transcription and Translation,,p(HGNC:TP53),
Oxidative Stress Induced Senescence,,p(HGNC:TP53),
Formation of Senescence-Associated Heterochromatin Foci (SAHF),,p(HGNC:TP53),
Oncogene Induced Senescence,,p(HGNC:TP53),
DNA Damage/Telomere Stress Induced Senescence,,p(HGNC:TP53),
SUMOylation of transcription factors,,p(HGNC:TP53),
Autodegradation of the E3 ubiquitin ligase COP1,,p(HGNC:TP53),
Association of TriC/CCT with target proteins during biosynthesis,,p(HGNC:TP53),
Pyroptosis,,p(HGNC:TP53),
TP53 Regulates Metabolic Genes,,p(HGNC:TP53),
Ub-specific processing proteases,,p(HGNC:TP53),
Ovarian tumor domain proteases,,p(HGNC:TP53),
Interleukin-4 and Interleukin-13 signaling,,p(HGNC:TP53); p(HGNC:BCL2); p(HGNC:JAK2),
TP53 Regulates Transcription of DNA Repair Genes,,p(HGNC:TP53),
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,,p(HGNC:TP53),
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,,p(HGNC:TP53),
TP53 Regulates Transcription of Caspase Activators and Caspases,,p(HGNC:TP53),
TP53 Regulates Transcription of Death Receptors and Ligands,,p(HGNC:TP53),
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,,p(HGNC:TP53),
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,,p(HGNC:TP53),
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,,p(HGNC:TP53),
Regulation of TP53 Expression,,p(HGNC:TP53),
Regulation of TP53 Activity through Phosphorylation,,p(HGNC:TP53),
Regulation of TP53 Degradation,,p(HGNC:TP53),
Regulation of TP53 Activity through Acetylation,,p(HGNC:TP53),
Regulation of TP53 Activity through Association with Co-factors,,p(HGNC:TP53),
Regulation of TP53 Activity through Methylation,,p(HGNC:TP53),
PI5P Regulates TP53 Acetylation,,p(HGNC:TP53),
G2/M DNA damage checkpoint,,p(HGNC:TP53),
G2/M Checkpoints,,p(HGNC:TP53),
Stabilization of p53,,p(HGNC:TP53),
Transcriptional activation of cell cycle inhibitor p21,,p(HGNC:TP53),
The role of GTSE1 in G2/M progression after G2 checkpoint,,p(HGNC:TP53),
Transcriptional Regulation by VENTX,,p(HGNC:TP53),
RUNX3 regulates CDKN1A transcription,,p(HGNC:TP53),
Regulation of PTEN gene transcription,,p(HGNC:TP53),
Loss of function of TP53 in cancer due to loss of tetramerization ability,,p(HGNC:TP53),
Signaling by ALK fusions and activated point mutants,,p(HGNC:TP53),
Regulation of NF-kappa B signaling,,p(HGNC:TP53),
Zygotic genome activation (ZGA),,p(HGNC:TP53),
PKR-mediated signaling,,p(HGNC:TP53),
RET signaling,,p(HGNC:RET); p(HGNC:PRKCA),
NPAS4 regulates expression of target genes,,p(HGNC:RET),
Formation of the nephric duct,,p(HGNC:RET),
Formation of the ureteric bud,,p(HGNC:RET),
Other interleukin signaling,,p(HGNC:CSF3R),
Transcriptional regulation of granulopoiesis,,p(HGNC:CSF3R); p(HGNC:RARA),
Signaling by CSF3 (G-CSF),,p(HGNC:CSF3R); p(HGNC:JAK2),
Inactivation of CSF3 (G-CSF) signaling,,p(HGNC:CSF3R); p(HGNC:JAK2),
Activation of BAD and translocation to mitochondria,,p(HGNC:BCL2),
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,,p(HGNC:BCL2),
The NLRP1 inflammasome,,p(HGNC:BCL2),
Estrogen-dependent gene expression,,p(HGNC:BCL2),
Estrogen-dependent nuclear events downstream of ESR-membrane signaling,,p(HGNC:BCL2),
NFE2L2 regulating tumorigenic genes,,p(HGNC:BCL2),
Regulation of MITF-M-dependent genes involved in apoptosis,,p(HGNC:BCL2),
Downstream TCR signaling,,p(HGNC:PRKCQ),
"Inactivation, recovery and regulation of the phototransduction cascade",,p(HGNC:PRKCQ); p(HGNC:PRKCA),
FCERI mediated NF-kB activation,,p(HGNC:PRKCQ),
Netrin-1 signaling,,p(HGNC:PRKCQ),
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,,p(HGNC:PRKCQ),
RAS processing,,p(HGNC:PRKCQ),
Transcription of E2F targets under negative control by DREAM complex,,p(HGNC:TOP2A),
SUMOylation of DNA replication proteins,,p(HGNC:TOP2A),
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,,p(HGNC:IDH1),
NADPH regeneration,,p(HGNC:IDH1),
Peroxisomal protein import,,p(HGNC:IDH1),
NFE2L2 regulating TCA cycle genes,,p(HGNC:IDH1),
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",,p(HGNC:PDGFRA),
Signaling by PDGFRA extracellular domain mutants,,p(HGNC:PDGFRA),
Imatinib-resistant PDGFR mutants,,p(HGNC:PDGFRA),
Sunitinib-resistant PDGFR mutants,,p(HGNC:PDGFRA),
Regorafenib-resistant PDGFR mutants,,p(HGNC:PDGFRA),
Sorafenib-resistant PDGFR mutants,,p(HGNC:PDGFRA),
PDGFR mutants bind TKIs,,p(HGNC:PDGFRA),
"Interleukin-3, Interleukin-5 and GM-CSF signaling",,p(HGNC:CSF2RA); p(HGNC:JAK2),
Surfactant metabolism,,p(HGNC:CSF2RA),
Defective CSF2RB causes SMDP5,,p(HGNC:CSF2RA),
Defective CSF2RA causes SMDP4,,p(HGNC:CSF2RA),
Interleukin receptor SHC signaling,,p(HGNC:CSF2RA); p(HGNC:JAK2),
Interleukin-6 signaling,,p(HGNC:JAK2),
MAPK3 (ERK1) activation,,p(HGNC:JAK2),
MAPK1 (ERK2) activation,,p(HGNC:JAK2),
Prolactin receptor signaling,,p(HGNC:JAK2),
Signaling by SCF-KIT,,p(HGNC:KIT); p(HGNC:JAK2); p(HGNC:PRKCA),
Signaling by Leptin,,p(HGNC:JAK2),
RMTs methylate histone arginines,,p(HGNC:DNMT3A); p(HGNC:JAK2),
RAF activation,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2),
IL-6-type cytokine receptor ligand interactions,,p(HGNC:JAK2),
Signaling by moderate kinase activity BRAF mutants,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2),
Signaling by BRAF and RAF1 fusions,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2),
Paradoxical activation of RAF signaling by kinase inactive BRAF,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2),
Regulation of IFNG signaling,,p(HGNC:JAK2),
Interleukin-20 family signaling,,p(HGNC:JAK2),
Interleukin-35 Signalling,,p(HGNC:JAK2),
Signaling by Erythropoietin,,p(HGNC:JAK2),
Interleukin-12 signaling,,p(HGNC:JAK2),
Interleukin-23 signaling,,p(HGNC:JAK2),
Interleukin-27 signaling,,p(HGNC:JAK2),
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),,p(HGNC:JAK2),
Erythropoietin activates Phospholipase C gamma (PLCG),,p(HGNC:JAK2),
Erythropoietin activates STAT5,,p(HGNC:JAK2),
Erythropoietin activates RAS,,p(HGNC:JAK2),
Signaling downstream of RAS mutants,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2),
Signaling by RAF1 mutants,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2),
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",,p(HGNC:KIT); p(HGNC:JAK2),
Potential therapeutics for SARS,,p(HGNC:JAK2),
IFNG signaling activates MAPKs,,p(HGNC:RAF1); p(HGNC:JAK2),
Growth hormone receptor signaling,,p(HGNC:JAK2),
Class B/2 (Secretin family receptors),,p(HGNC:SMO),
Hedgehog 'off' state,,p(HGNC:SMO),
BBSome-mediated cargo-targeting to cilium,,p(HGNC:SMO),
Hedgehog 'on' state,,p(HGNC:SMO),
Activation of SMO,,p(HGNC:SMO),
Sphingolipid de novo biosynthesis,,p(HGNC:PRKD3),
SUMOylation of intracellular receptors,,p(HGNC:RARA),
TGFBR3 expression,,p(HGNC:RARA),
VEGFA-VEGFR2 Pathway,,p(HGNC:AXL); p(HGNC:KDR),
Transcriptional regulation of testis differentiation,,p(HGNC:WT1),
Nephron development,,p(HGNC:WT1),
Stimuli-sensing channels,,p(HGNC:RAF1),
Rap1 signalling,,p(HGNC:RAF1),
GP1b-IX-V activation signalling,,p(HGNC:RAF1),
CD209 (DC-SIGN) signaling,,p(HGNC:RAF1),
MAP2K and MAPK activation,,p(HGNC:RAF1); p(HGNC:BRAF),
Negative feedback regulation of MAPK pathway,,p(HGNC:RAF1); p(HGNC:BRAF),
Negative regulation of MAPK pathway,,p(HGNC:RAF1); p(HGNC:BRAF),
Signaling by high-kinase activity BRAF mutants,,p(HGNC:RAF1); p(HGNC:BRAF),
SHOC2 M1731 mutant abolishes MRAS complex function,,p(HGNC:RAF1); p(HGNC:BRAF),
Gain-of-function MRAS complexes activate RAF signaling,,p(HGNC:RAF1); p(HGNC:BRAF),
PRC2 methylates histones and DNA,,p(HGNC:DNMT3A); p(HGNC:DNMT1),
NoRC negatively regulates rRNA expression,,p(HGNC:DNMT1),
SUMOylation of DNA methylation proteins,,p(HGNC:DNMT3A); p(HGNC:DNMT1),
DNA methylation,,p(HGNC:DNMT3A); p(HGNC:DNMT1),
STAT3 nuclear events downstream of ALK signaling,,p(HGNC:DNMT1),
Nuclear events stimulated by ALK signaling in cancer,,p(HGNC:DNMT1),
Regulation of KIT signaling,,p(HGNC:KIT); p(HGNC:PRKCA),
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,,p(HGNC:KIT),
Dasatinib-resistant KIT mutants,,p(HGNC:KIT),
Imatinib-resistant KIT mutants,,p(HGNC:KIT),
KIT mutants bind TKIs,,p(HGNC:KIT),
Masitinib-resistant KIT mutants,,p(HGNC:KIT),
Nilotinib-resistant KIT mutants,,p(HGNC:KIT),
Regorafenib-resistant KIT mutants,,p(HGNC:KIT),
Signaling by kinase domain mutants of KIT,,p(HGNC:KIT),
Sunitinib-resistant KIT mutants,,p(HGNC:KIT),
Signaling by juxtamembrane domain KIT mutants,,p(HGNC:KIT),
Sorafenib-resistant KIT mutants,,p(HGNC:KIT),
Signaling by extracellular domain mutants of KIT,,p(HGNC:KIT),
Transcriptional and post-translational regulation of MITF-M expression and activity,,p(HGNC:KIT),
Disinhibition of SNARE formation,,p(HGNC:PRKCA),
EGFR Transactivation by Gastrin,,p(HGNC:PRKCA),
Syndecan interactions,,p(HGNC:PRKCA),
Acetylcholine regulates insulin secretion,,p(HGNC:PRKCA),
Ca2+ pathway,,p(HGNC:PRKCA),
Trafficking of GluR2-containing AMPA receptors,,p(HGNC:PRKCA),
Depolymerization of the Nuclear Lamina,,p(HGNC:PRKCA),
WNT5A-dependent internalization of FZD4,,p(HGNC:PRKCA),
Response to elevated platelet cytosolic Ca2+,,p(HGNC:PRKCA),
ROBO receptors bind AKAP5,,p(HGNC:PRKCA),
Spry regulation of FGF signaling,,p(HGNC:BRAF),
Frs2-mediated activation,,p(HGNC:BRAF),
ARMS-mediated activation,,p(HGNC:BRAF),
Signalling to p38 via RIT and RIN,,p(HGNC:BRAF),
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs),,p(HGNC:DNMT3A),
VEGF binds to VEGFR leading to receptor dimerization,,p(HGNC:KDR); p(HGNC:FLT4),
NOTCH4 Intracellular Domain Regulates Transcription,,p(HGNC:FLT4),
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,,p(HGNC:KDR); p(HGNC:FLT4),
Neurophilin interactions with VEGF and VEGFR,,p(HGNC:KDR),
Integrin cell surface interactions,,p(HGNC:KDR),
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,,p(HGNC:KDR),
Fanconi Anemia Pathwa,,p(HGNC:FANCG); p(HGNC:FANCF); p(HGNC:FANCC); p(HGNC:UBE2T); p(HGNC:FANCA); p(HGNC:FANCB); p(HGNC:FANCE); p(HGNC:ERCC4); p(HGNC:FANCD2); p(HGNC:FANCI); p(HGNC:RPS27A); p(HGNC:FANCL); p(HGNC:SLX4),
PKR-mediated signalin,,p(HGNC:TP53); p(HGNC:FANCG); p(HGNC:FANCF); p(HGNC:FANCC); p(HGNC:FANCA); p(HGNC:FANCB); p(HGNC:FANCE); p(HGNC:NPM1); p(HGNC:FANCL),
PRC2 methylates histones and DN,,p(HGNC:DNMT3A); p(HGNC:DNMT1); p(HGNC:EZH2),
RMTs methylate histone arginine,,p(HGNC:DNMT3A); p(HGNC:JAK2),
SUMOylation of DNA methylation protein,,p(HGNC:DNMT3A); p(HGNC:DNMT1),
DNA methylatio,,p(HGNC:DNMT3A); p(HGNC:DNMT1),
Defective pyroptosi,,p(HGNC:POLA1); p(HGNC:DNMT3A); p(HGNC:DNMT1); p(HGNC:POLA2); p(HGNC:PRIM1); p(HGNC:PRIM2); p(HGNC:EZH2),
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs,,p(HGNC:DNMT3A),
Activation of BAD and translocation to mitochondri,,p(HGNC:BCL2),
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 member,,p(HGNC:BCL2),
Interleukin-4 and Interleukin-13 signalin,,p(HGNC:TP53); p(HGNC:BCL2); p(HGNC:JAK2),
The NLRP1 inflammasom,,p(HGNC:BCL2),
Estrogen-dependent gene expressio,,p(HGNC:BCL2); p(HGNC:RUNX1); p(HGNC:STAG2); p(HGNC:RAD21),
Estrogen-dependent nuclear events downstream of ESR-membrane signalin,,p(HGNC:BCL2),
NFE2L2 regulating tumorigenic gene,,p(HGNC:BCL2),
Regulation of MITF-M-dependent genes involved in apoptosi,,p(HGNC:BCL2),
Pre-NOTCH Transcription and Translatio,,p(HGNC:TP53); p(HGNC:RUNX1); p(HGNC:PRKCI),
Organic cation transpor,,p(HGNC:RUNX1),
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs,,p(HGNC:RUNX1),
RUNX1 regulates estrogen receptor mediated transcriptio,,p(HGNC:RUNX1),
Regulation of RUNX1 Expression and Activit,,p(HGNC:RUNX1); p(HGNC:PML); p(HGNC:PTPN11),
RUNX1 regulates expression of components of tight junction,,p(HGNC:RUNX1),
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functio,,p(HGNC:PRKCQ); p(HGNC:RUNX1); p(HGNC:KMT2A); p(HGNC:GATA1),
RUNX1 regulates transcription of genes involved in differentiation of HSC,,p(HGNC:ABL1); p(HGNC:RUNX1); p(HGNC:GATA2); p(HGNC:KMT2A); p(HGNC:RPS27A); p(HGNC:GATA1),
RUNX1 regulates transcription of genes involved in differentiation of keratinocyte,,p(HGNC:RUNX1),
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not know,,p(HGNC:RUNX1),
RUNX1 regulates transcription of genes involved in BCR signalin,,p(HGNC:RUNX1),
RUNX1 regulates transcription of genes involved in differentiation of myeloid cell,,p(HGNC:RUNX1); p(HGNC:PRKCB),
RUNX1 regulates transcription of genes involved in interleukin signalin,,p(HGNC:RUNX1),
RUNX1 regulates transcription of genes involved in WNT signalin,,p(HGNC:RUNX1),
RUNX2 regulates genes involved in differentiation of myeloid cell,,p(HGNC:RUNX1),
RUNX3 regulates p14-AR,,p(HGNC:RUNX1); p(HGNC:KRAS),
Transcriptional regulation of granulopoiesi,,p(HGNC:CSF3R); p(HGNC:RARA); p(HGNC:RUNX1); p(HGNC:CEBPA); p(HGNC:GATA2); p(HGNC:KMT2A),
SARS-CoV-1 activates/modulates innate immune response,,p(HGNC:RUNX1); p(HGNC:RPS27A),
Transcription of E2F targets under negative control by DREAM comple,,p(HGNC:TOP2A),
SUMOylation of DNA replication protein,,p(HGNC:TOP2A); p(HGNC:NUP98),
Effects of PIP2 hydrolysi,,p(HGNC:PRKCD); p(HGNC:PRKCE); p(HGNC:PRKCH); p(HGNC:PRKCQ),
G alpha (z) signalling event,,p(HGNC:PRKCD); p(HGNC:PRKCE); p(HGNC:PRKCH); p(HGNC:PRKCQ); p(HGNC:PRKCA); p(HGNC:PRKCB); p(HGNC:PRKCG),
Nuclear Receptor transcription pathwa,,p(HGNC:RARG); p(HGNC:RARA); p(HGNC:RARB),
SUMOylation of intracellular receptor,,p(HGNC:RARA),
Signaling by Retinoic Aci,,p(HGNC:RARG); p(HGNC:RARA); p(HGNC:RARB),
Activation of anterior HOX genes in hindbrain development during early embryogenesi,,p(HGNC:RARG); p(HGNC:RARA); p(HGNC:RARB); p(HGNC:EZH2),
TGFBR3 expressio,,p(HGNC:RARA),
L13a-mediated translational silencing of Ceruloplasmin expressio,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
Peptide chain elongatio,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
SRP-dependent cotranslational protein targeting to membran,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
Viral mRNA Translatio,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
Selenocysteine synthesi,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
Major pathway of rRNA processing in the nucleolus and cytoso,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
Translation initiation complex formatio,,p(HGNC:RPS29); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPS24),
Formation of a pool of free 40S subunit,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
"Formation of the ternary complex, and subsequently, the 43S comple",,p(HGNC:RPS29); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPS24),
Ribosomal scanning and start codon recognitio,,p(HGNC:RPS29); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPS24),
GTP hydrolysis and joining of the 60S ribosomal subuni,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
Eukaryotic Translation Terminatio,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
Regulation of expression of SLITs and ROBO,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
Response of EIF2AK4 (GCN2) to amino acid deficienc,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
SARS-CoV-1 modulates host translation machiner,,p(HGNC:RPS29); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPS24),
SARS-CoV-2 modulates host translation machiner,,p(HGNC:RPS29); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPS24),
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,,p(HGNC:RPS29); p(HGNC:RPL35A); p(HGNC:RPL36); p(HGNC:RPL23); p(HGNC:RPL5); p(HGNC:RPL11); p(HGNC:RPS27); p(HGNC:RPS26); p(HGNC:RPL31); p(HGNC:RPS7); p(HGNC:RPS10); p(HGNC:RPS19); p(HGNC:RPS17); p(HGNC:RPS28); p(HGNC:RPS27A); p(HGNC:RPL15); p(HGNC:RPL26); p(HGNC:RPS24),
PI3K Cascad,,p(HGNC:FLT3); p(HGNC:PTPN11),
PIP3 activates AKT signalin,,p(HGNC:FLT3); p(HGNC:KIT); p(HGNC:PDGFRB); p(HGNC:PDGFRA); p(HGNC:PTPN11),
Constitutive Signaling by Aberrant PI3K in Cance,,p(HGNC:FLT3); p(HGNC:KIT); p(HGNC:PDGFRB); p(HGNC:PDGFRA); p(HGNC:PTPN11),
RAF/MAP kinase cascad,,p(HGNC:FLT3); p(HGNC:KIT); p(HGNC:PDGFRB); p(HGNC:RET); p(HGNC:CSF2RA); p(HGNC:PDGFRA); p(HGNC:JAK2); p(HGNC:KRAS); p(HGNC:NRAS),
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",,p(HGNC:FLT3); p(HGNC:KIT); p(HGNC:PDGFRB); p(HGNC:PDGFRA); p(HGNC:PTPN11),
FLT3 Signalin,,p(HGNC:FLT3); p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
STAT5 Activatio,,p(HGNC:FLT3); p(HGNC:STAT5B); p(HGNC:PTPN11),
FLT3 mutants bind TKI,,p(HGNC:FLT3),
STAT5 activation downstream of FLT3 ITD mutant,,p(HGNC:FLT3); p(HGNC:STAT5B); p(HGNC:PTPN11),
KW2449-resistant FLT3 mutant,,p(HGNC:FLT3),
semaxanib-resistant FLT3 mutant,,p(HGNC:FLT3),
crenolanib-resistant FLT3 mutant,,p(HGNC:FLT3),
gilteritinib-resistant FLT3 mutant,,p(HGNC:FLT3),
lestaurtinib-resistant FLT3 mutant,,p(HGNC:FLT3),
midostaurin-resistant FLT3 mutant,,p(HGNC:FLT3),
pexidartinib-resistant FLT3 mutant,,p(HGNC:FLT3),
ponatinib-resistant FLT3 mutant,,p(HGNC:FLT3),
quizartinib-resistant FLT3 mutant,,p(HGNC:FLT3),
sorafenib-resistant FLT3 mutant,,p(HGNC:FLT3),
sunitinib-resistant FLT3 mutant,,p(HGNC:FLT3),
tandutinib-resistant FLT3 mutant,,p(HGNC:FLT3),
linifanib-resistant FLT3 mutant,,p(HGNC:FLT3),
tamatinib-resistant FLT3 mutant,,p(HGNC:FLT3),
Signaling by FLT3 ITD and TKD mutant,,p(HGNC:FLT3); p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
Negative regulation of FLT,,p(HGNC:FLT3); p(HGNC:CBL); p(HGNC:RPS27A),
FLT3 signaling through SRC family kinase,,p(HGNC:FLT3),
FLT3 signaling by CBL mutant,,p(HGNC:FLT3); p(HGNC:CBL); p(HGNC:RPS27A),
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarat,,p(HGNC:IDH1),
NADPH regeneratio,,p(HGNC:IDH1),
Neutrophil degranulatio,,p(HGNC:IDH1); p(HGNC:PRKCD); p(HGNC:CD33); p(HGNC:ELANE); p(HGNC:NRAS),
Peroxisomal protein impor,,p(HGNC:IDH1); p(HGNC:RPS27A),
NFE2L2 regulating TCA cycle gene,,p(HGNC:IDH1),
Telomere Extension By Telomeras,,p(HGNC:DKC1); p(HGNC:TERT); p(HGNC:NOP10); p(HGNC:WRAP53); p(HGNC:ACD); p(HGNC:NHP2); p(HGNC:TINF2); p(HGNC:RTEL1),
rRNA modification in the nucleus and cytoso,,p(HGNC:DKC1); p(HGNC:NOP10); p(HGNC:RPS7); p(HGNC:NHP2),
UCH proteinase,,p(HGNC:ASXL1); p(HGNC:RPS27A),
Transcriptional regulation of white adipocyte differentiatio,,p(HGNC:CEBPA),
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,,p(HGNC:ABL1); p(HGNC:CEBPA),
VEGF binds to VEGFR leading to receptor dimerizatio,,p(HGNC:KDR); p(HGNC:FLT4),
NOTCH4 Intracellular Domain Regulates Transcriptio,,p(HGNC:FLT4),
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,,p(HGNC:KDR); p(HGNC:FLT4),
Disinhibition of SNARE formatio,,p(HGNC:PRKCA); p(HGNC:PRKCB); p(HGNC:PRKCG),
Activation of NF-kappaB in B cell,,p(HGNC:PRKCB); p(HGNC:RPS27A),
Trafficking of GluR2-containing AMPA receptor,,p(HGNC:PRKCA); p(HGNC:PRKCB); p(HGNC:PRKCG),
Depolymerization of the Nuclear Lamin,,p(HGNC:PRKCA); p(HGNC:PRKCB),
WNT5A-dependent internalization of FZD,,p(HGNC:PRKCA); p(HGNC:PRKCB); p(HGNC:PRKCG),
VEGFR2 mediated cell proliferatio,,p(HGNC:KDR); p(HGNC:PRKCD); p(HGNC:PRKCA); p(HGNC:PRKCB); p(HGNC:PRKCZ); p(HGNC:KRAS); p(HGNC:NRAS),
RHO GTPases Activate NADPH Oxidase,,p(HGNC:PRKCD); p(HGNC:PRKCA); p(HGNC:PRKCB); p(HGNC:PRKCZ),
Response to elevated platelet cytosolic Ca2,,p(HGNC:PRKCA); p(HGNC:PRKCB); p(HGNC:PRKCG),
Formation of the beta-catenin:TCF transactivating comple,,p(HGNC:TERT),
"Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescenc",,p(HGNC:TERT),
VEGFA-VEGFR2 Pathwa,,p(HGNC:AXL); p(HGNC:KDR),
Recognition of DNA damage by PCNA-containing replication comple,,p(HGNC:POLE); p(HGNC:POLE2); p(HGNC:POLD4); p(HGNC:RPS27A); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLE3); p(HGNC:POLD2),
PCNA-Dependent Long Patch Base Excision Repai,,p(HGNC:POLE); p(HGNC:POLE2); p(HGNC:POLD4); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLE3); p(HGNC:POLD2),
Termination of translesion DNA synthesi,,p(HGNC:POLE); p(HGNC:POLE2); p(HGNC:POLD4); p(HGNC:RPS27A); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLE3); p(HGNC:POLD2),
HDR through Homologous Recombination (HRR,,p(HGNC:POLE); p(HGNC:XRCC2); p(HGNC:POLE2); p(HGNC:POLD4); p(HGNC:RPS27A); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLE3); p(HGNC:POLD2); p(HGNC:PALB2),
Gap-filling DNA repair synthesis and ligation in GG-NE,,p(HGNC:POLE); p(HGNC:POLE2); p(HGNC:POLD4); p(HGNC:RPS27A); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLE3); p(HGNC:POLD2),
Dual Incision in GG-NE,,p(HGNC:POLE); p(HGNC:POLE2); p(HGNC:POLD4); p(HGNC:ERCC4); p(HGNC:RPS27A); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLE3); p(HGNC:POLD2),
Dual incision in TC-NE,,p(HGNC:POLE); p(HGNC:POLE2); p(HGNC:POLD4); p(HGNC:ERCC4); p(HGNC:RPS27A); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLE3); p(HGNC:POLD2),
Gap-filling DNA repair synthesis and ligation in TC-NE,,p(HGNC:POLE); p(HGNC:POLE2); p(HGNC:POLD4); p(HGNC:RPS27A); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLE3); p(HGNC:POLD2),
DNA replication initiatio,,p(HGNC:POLA1); p(HGNC:POLE); p(HGNC:POLA2); p(HGNC:PRIM1); p(HGNC:POLE2); p(HGNC:PRIM2); p(HGNC:POLE3),
Activation of the pre-replicative comple,,p(HGNC:POLA1); p(HGNC:POLE); p(HGNC:POLA2); p(HGNC:PRIM1); p(HGNC:POLE2); p(HGNC:PRIM2); p(HGNC:POLE3),
GPVI-mediated activation cascad,,p(HGNC:PRKCZ); p(HGNC:PTPN11),
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition,,p(HGNC:PRKCZ); p(HGNC:RPS27A),
Estrogen-stimulated signaling through PRKC,,p(HGNC:PRKCZ); p(HGNC:KRAS); p(HGNC:NRAS),
Regulation of RAS by GAP,,p(HGNC:NF1); p(HGNC:RPS27A); p(HGNC:KRAS); p(HGNC:NRAS),
RAS signaling downstream of NF1 loss-of-function variant,,p(HGNC:NF1); p(HGNC:KRAS); p(HGNC:NRAS),
TP53 Regulates Transcription of DNA Repair Gene,,p(HGNC:TP53); p(HGNC:FANCC); p(HGNC:FANCD2); p(HGNC:FANCI),
Transport of Mature mRNA derived from an Intron-Containing Transcrip,,p(HGNC:SRSF2); p(HGNC:NUP98); p(HGNC:U2AF1),
mRNA Splicing - Major Pathwa,,p(HGNC:SRSF2); p(HGNC:U2AF1); p(HGNC:SF3B1); p(HGNC:DDX41),
mRNA Splicing - Minor Pathwa,,p(HGNC:SRSF2); p(HGNC:SF3B1),
mRNA 3'-end processin,,p(HGNC:SRSF2); p(HGNC:U2AF1),
Processing of Capped Intron-Containing Pre-mRN,,p(HGNC:SRSF2),
RNA Polymerase II Transcription Terminatio,,p(HGNC:SRSF2); p(HGNC:U2AF1),
Translesion synthesis by REV,,p(HGNC:MAD2L2); p(HGNC:RPS27A),
Translesion synthesis by POL,,p(HGNC:MAD2L2); p(HGNC:RPS27A),
Synthesis of active ubiquitin: roles of E1 and E2 enzyme,,p(HGNC:UBE2T); p(HGNC:RPS27A),
"Interleukin-3, Interleukin-5 and GM-CSF signalin",,p(HGNC:CSF2RA); p(HGNC:JAK2); p(HGNC:STAT5B); p(HGNC:PTPN11),
Surfactant metabolis,,p(HGNC:CSF2RA),
Defective CSF2RB causes SMDP,,p(HGNC:CSF2RA),
Defective CSF2RA causes SMDP,,p(HGNC:CSF2RA),
Interleukin receptor SHC signalin,,p(HGNC:CSF2RA); p(HGNC:JAK2),
Inhibition of replication initiation of damaged DNA by RB1/E2F,,p(HGNC:POLA1); p(HGNC:POLA2); p(HGNC:PRIM1); p(HGNC:PRIM2),
Polymerase switching on the C-strand of the telomer,,p(HGNC:POLA1); p(HGNC:POLA2); p(HGNC:PRIM1); p(HGNC:ACD); p(HGNC:POLD4); p(HGNC:PRIM2); p(HGNC:TINF2); p(HGNC:POLD3); p(HGNC:CTC1); p(HGNC:POLD1); p(HGNC:STN1); p(HGNC:POLD2),
Telomere C-strand synthesis initiatio,,p(HGNC:POLA1); p(HGNC:POLA2); p(HGNC:PRIM1); p(HGNC:ACD); p(HGNC:PRIM2); p(HGNC:TINF2); p(HGNC:CTC1); p(HGNC:STN1),
Polymerase switchin,,p(HGNC:POLA1); p(HGNC:POLA2); p(HGNC:PRIM1); p(HGNC:POLD4); p(HGNC:PRIM2); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLD2),
Removal of the Flap Intermediat,,p(HGNC:POLA1); p(HGNC:POLA2); p(HGNC:PRIM1); p(HGNC:POLD4); p(HGNC:PRIM2); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLD2),
Processive synthesis on the lagging stran,,p(HGNC:POLA1); p(HGNC:POLA2); p(HGNC:PRIM1); p(HGNC:POLD4); p(HGNC:PRIM2); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLD2),
Stimuli-sensing channel,,p(HGNC:RAF1); p(HGNC:RPS27A),
Rap1 signallin,,p(HGNC:RAF1),
GP1b-IX-V activation signallin,,p(HGNC:RAF1),
CD209 (DC-SIGN) signalin,,p(HGNC:RAF1); p(HGNC:KRAS); p(HGNC:NRAS),
RAF activatio,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2); p(HGNC:KRAS); p(HGNC:NRAS),
MAP2K and MAPK activatio,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:KRAS); p(HGNC:NRAS),
Negative feedback regulation of MAPK pathwa,,p(HGNC:RAF1); p(HGNC:BRAF),
Negative regulation of MAPK pathwa,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:RPS27A); p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by moderate kinase activity BRAF mutant,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2); p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by high-kinase activity BRAF mutant,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by BRAF and RAF1 fusion,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2); p(HGNC:KRAS); p(HGNC:NRAS),
Paradoxical activation of RAF signaling by kinase inactive BRA,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2); p(HGNC:KRAS); p(HGNC:NRAS),
Signaling downstream of RAS mutant,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2); p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by RAF1 mutant,,p(HGNC:RAF1); p(HGNC:BRAF); p(HGNC:JAK2); p(HGNC:KRAS); p(HGNC:NRAS),
SHOC2 M1731 mutant abolishes MRAS complex functio,,p(HGNC:RAF1); p(HGNC:BRAF),
Gain-of-function MRAS complexes activate RAF signalin,,p(HGNC:RAF1); p(HGNC:BRAF),
IFNG signaling activates MAPK,,p(HGNC:RAF1); p(HGNC:JAK2),
Meiotic synapsi,,p(HGNC:STAG2); p(HGNC:ACD); p(HGNC:RAD21); p(HGNC:TINF2),
Separation of Sister Chromatid,,p(HGNC:STAG2); p(HGNC:RPS27); p(HGNC:RAD21); p(HGNC:RPS27A),
Establishment of Sister Chromatid Cohesio,,p(HGNC:STAG2); p(HGNC:RAD21),
Cohesin Loading onto Chromati,,p(HGNC:STAG2); p(HGNC:RAD21),
Resolution of Sister Chromatid Cohesio,,p(HGNC:STAG2); p(HGNC:RPS27); p(HGNC:RAD21),
SUMOylation of DNA damage response and repair protein,,p(HGNC:STAG2); p(HGNC:NUP98); p(HGNC:RAD21); p(HGNC:PML),
RET signalin,,p(HGNC:RET); p(HGNC:PRKCA); p(HGNC:PTPN11),
NPAS4 regulates expression of target gene,,p(HGNC:RET),
Formation of the nephric duc,,p(HGNC:RET),
Formation of the ureteric bu,,p(HGNC:RET),
Apoptotic cleavage of cellular protein,,p(HGNC:PRKCD); p(HGNC:PRKCQ),
Calmodulin induced event,,p(HGNC:PRKCD); p(HGNC:PRKCA); p(HGNC:PRKCG),
SHC1 events in ERBB2 signalin,,p(HGNC:PRKCD); p(HGNC:PRKCE); p(HGNC:PRKCA); p(HGNC:KRAS); p(HGNC:NRAS),
DAG and IP3 signalin,,p(HGNC:PRKCD); p(HGNC:PRKCE),
Role of phospholipids in phagocytosi,,p(HGNC:PRKCD); p(HGNC:PRKCE),
HuR (ELAVL1) binds and stabilizes mRN,,p(HGNC:PRKCD); p(HGNC:PRKCA),
CLEC7A (Dectin-1) signalin,,p(HGNC:PRKCD); p(HGNC:RPS27A),
Interferon gamma signalin,,p(HGNC:JAK2); p(HGNC:PRKCD); p(HGNC:PML),
KEAP1-NFE2L2 pathwa,,p(HGNC:PRKCD); p(HGNC:PRKCI); p(HGNC:RPS27A); p(HGNC:PALB2),
NoRC negatively regulates rRNA expressio,,p(HGNC:DNMT1),
STAT3 nuclear events downstream of ALK signalin,,p(HGNC:DNMT1),
Nuclear events stimulated by ALK signaling in cance,,p(HGNC:DNMT1); p(HGNC:NPM1),
Sphingolipid de novo biosynthesi,,p(HGNC:PRKD3); p(HGNC:PRKD1),
ISG15 antiviral mechanis,,p(HGNC:NUP98); p(HGNC:RPS27A),
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal. [P52948-,,p(HGNC:NUP98),
Transport of the SLBP independent Mature mRN,,p(HGNC:NUP98),
Transport of the SLBP Dependant Mature mRN,,p(HGNC:NUP98),
Transport of Mature mRNA Derived from an Intronless Transcrip,,p(HGNC:NUP98),
Rev-mediated nuclear export of HIV RN,,p(HGNC:NUP98),
Transport of Ribonucleoproteins into the Host Nucleu,,p(HGNC:NUP98),
NS1 Mediated Effects on Host Pathway,,p(HGNC:NUP98),
Viral Messenger RNA Synthesi,,p(HGNC:NUP98),
NEP/NS2 Interacts with the Cellular Export Machiner,,p(HGNC:NUP98),
Regulation of Glucokinase by Glucokinase Regulatory Protei,,p(HGNC:NUP98),
Nuclear import of Rev protei,,p(HGNC:NUP98); p(HGNC:NPM1),
Vpr-mediated nuclear import of PIC,,p(HGNC:NUP98),
snRNP Assembl,,p(HGNC:NUP98),
Separation of Sister Chromatids. [P52948-,,p(HGNC:NUP98),
Resolution of Sister Chromatid Cohesion. [P52948-,,p(HGNC:NUP98),
SUMOylation of ubiquitinylation protein,,p(HGNC:NUP98); p(HGNC:PML),
Nuclear Pore Complex (NPC) Disassembl,,p(HGNC:NUP98),
Regulation of HSF1-mediated heat shock respons,,p(HGNC:NUP98),
SUMOylation of SUMOylation protein,,p(HGNC:NUP98),
SUMOylation of chromatin organization protein,,p(HGNC:NUP98),
SUMOylation of RNA binding protein,,p(HGNC:NUP98),
Transcriptional regulation by small RNA,,p(HGNC:NUP98),
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC,,p(HGNC:NUP98),
RHO GTPases Activate Formins. [P52948-,,p(HGNC:NUP98),
tRNA processing in the nucleu,,p(HGNC:NUP98),
Mitotic Prometaphase. [P52948-,,p(HGNC:NUP98),
HCMV Early Event,,p(HGNC:NUP98); p(HGNC:PML); p(HGNC:EZH2),
HCMV Late Event,,p(HGNC:NUP98),
Postmitotic nuclear pore complex (NPC) reformation. [P52948-,,p(HGNC:NUP98),
EML4 and NUDC in mitotic spindle formation. [P52948-,,p(HGNC:NUP98),
SARS-CoV-2 activates/modulates innate and adaptive immune response,,p(HGNC:NUP98); p(HGNC:RPS27A); p(HGNC:PTPN11),
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA,,p(HGNC:XRCC2); p(HGNC:RTEL1); p(HGNC:PALB2),
Resolution of D-loop Structures through Holliday Junction Intermediate,,p(HGNC:XRCC2); p(HGNC:SLX4); p(HGNC:PALB2),
Homologous DNA Pairing and Strand Exchang,,p(HGNC:XRCC2); p(HGNC:PALB2),
Presynaptic phase of homologous DNA pairing and strand exchang,,p(HGNC:XRCC2),
Defective homologous recombination repair (HRR) due to BRCA1 loss of functio,,p(HGNC:XRCC2); p(HGNC:PALB2),
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding functio,,p(HGNC:XRCC2); p(HGNC:PALB2),
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding functio,,p(HGNC:XRCC2); p(HGNC:PALB2),
Impaired BRCA2 binding to PALB,,p(HGNC:XRCC2); p(HGNC:PALB2),
Collagen degradatio,,p(HGNC:ELANE),
Degradation of the extracellular matri,,p(HGNC:ELANE),
Activation of Matrix Metalloproteinase,,p(HGNC:ELANE),
Pyroptosi,,p(HGNC:TP53); p(HGNC:ELANE),
Antimicrobial peptide,,p(HGNC:ELANE),
Regulation of Complement cascad,,p(HGNC:ELANE),
Expression of NOTCH2NL gene,,p(HGNC:ELANE),
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signa,,p(HGNC:RPS27),
RHO GTPases Activate Formin,,p(HGNC:RPS27),
Mitotic Prometaphas,,p(HGNC:RPS27),
EML4 and NUDC in mitotic spindle formatio,,p(HGNC:RPS27),
Association of TriC/CCT with target proteins during biosynthesi,,p(HGNC:TP53); p(HGNC:WRAP53),
Interleukin-6 signalin,,p(HGNC:JAK2); p(HGNC:CBL); p(HGNC:PTPN11),
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variant,,p(HGNC:CBL); p(HGNC:RPS27A); p(HGNC:KRAS); p(HGNC:NRAS),
Spry regulation of FGF signalin,,p(HGNC:BRAF); p(HGNC:CBL); p(HGNC:RPS27A); p(HGNC:PTPN11),
Regulation of KIT signalin,,p(HGNC:KIT); p(HGNC:PRKCA); p(HGNC:CBL),
EGFR downregulatio,,p(HGNC:CBL); p(HGNC:RPS27A),
TGF-beta receptor signaling activates SMAD,,p(HGNC:CBL),
Constitutive Signaling by EGFRvII,,p(HGNC:CBL); p(HGNC:KRAS); p(HGNC:NRAS),
Negative regulation of FGFR1 signalin,,p(HGNC:CBL); p(HGNC:RPS27A); p(HGNC:PTPN11),
Negative regulation of FGFR2 signalin,,p(HGNC:CBL); p(HGNC:RPS27A); p(HGNC:PTPN11),
Negative regulation of FGFR3 signalin,,p(HGNC:CBL); p(HGNC:RPS27A); p(HGNC:PTPN11),
Negative regulation of FGFR4 signalin,,p(HGNC:CBL); p(HGNC:RPS27A); p(HGNC:PTPN11),
Negative regulation of MET activit,,p(HGNC:CBL); p(HGNC:RPS27A),
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK,,p(HGNC:CBL); p(HGNC:RPS27A),
Cargo recognition for clathrin-mediated endocytosi,,p(HGNC:CBL); p(HGNC:RPS27A),
Clathrin-mediated endocytosi,,p(HGNC:CBL); p(HGNC:RPS27A),
InlB-mediated entry of Listeria monocytogenes into host cel,,p(HGNC:CBL); p(HGNC:RPS27A),
Regulation of signaling by CB,,p(HGNC:CBL); p(HGNC:RPS27A),
Signaling by CSF1 (M-CSF) in myeloid cell,,p(HGNC:CBL); p(HGNC:RPS27A); p(HGNC:KRAS); p(HGNC:PTPN11),
Downstream TCR signalin,,p(HGNC:PRKCQ); p(HGNC:RPS27A); p(HGNC:PTEN),
"Inactivation, recovery and regulation of the phototransduction cascad",,p(HGNC:PRKCQ); p(HGNC:PRKCA),
FCERI mediated NF-kB activatio,,p(HGNC:PRKCQ); p(HGNC:RPS27A),
Netrin-1 signalin,,p(HGNC:PRKCQ),
RAS processin,,p(HGNC:PRKCQ); p(HGNC:RPS27A); p(HGNC:KRAS); p(HGNC:NRAS),
Other interleukin signalin,,p(HGNC:CSF3R),
Signaling by CSF3 (G-CSF,,p(HGNC:CSF3R); p(HGNC:JAK2); p(HGNC:STAT5B); p(HGNC:KRAS); p(HGNC:PTPN11),
Inactivation of CSF3 (G-CSF) signalin,,p(HGNC:CSF3R); p(HGNC:JAK2); p(HGNC:RPS27A); p(HGNC:STAT5B),
Recognition and association of DNA glycosylase with site containing an affected pyrimidin,,p(HGNC:ACD); p(HGNC:TINF2); p(HGNC:MBD4),
Cleavage of the damaged pyrimidin,,p(HGNC:ACD); p(HGNC:TINF2); p(HGNC:MBD4),
Recognition and association of DNA glycosylase with site containing an affected purin,,p(HGNC:ACD); p(HGNC:TINF2),
Cleavage of the damaged purin,,p(HGNC:ACD); p(HGNC:TINF2),
Packaging Of Telomere End,,p(HGNC:ACD); p(HGNC:TINF2),
Processive synthesis on the C-strand of the telomer,,p(HGNC:ACD); p(HGNC:POLD4); p(HGNC:TINF2); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLD2),
Telomere C-strand (Lagging Strand) Synthesi,,p(HGNC:ACD); p(HGNC:POLD4); p(HGNC:TINF2); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLD2),
Removal of the Flap Intermediate from the C-stran,,p(HGNC:ACD); p(HGNC:POLD4); p(HGNC:TINF2); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLD2),
DNA Damage/Telomere Stress Induced Senescenc,,p(HGNC:TP53); p(HGNC:ACD); p(HGNC:TINF2),
Inhibition of DNA recombination at telomer,,p(HGNC:ACD); p(HGNC:TINF2),
NOTCH3 Intracellular Domain Regulates Transcription. [Q13422-,,p(HGNC:IKZF1),
p75NTR recruits signalling complexe,,p(HGNC:PRKCI); p(HGNC:RPS27A),
Tight junction interaction,,p(HGNC:PRKCI),
Regulation of actin dynamics for phagocytic cup formatio,,p(HGNC:ABL1),
Role of ABL in ROBO-SLIT signalin,,p(HGNC:ABL1),
Myogenesi,,p(HGNC:ABL1),
RHO GTPases Activate WASPs and WAVE,,p(HGNC:ABL1),
HDR through Single Strand Annealing (SSA,,p(HGNC:ABL1); p(HGNC:ERCC4),
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,,p(HGNC:ABL1); p(HGNC:TP53); p(HGNC:RPS27A),
Cyclin D associated events in G,,p(HGNC:ABL1); p(HGNC:JAK2); p(HGNC:RPS27A),
RUNX2 regulates osteoblast differentiatio,,p(HGNC:ABL1),
FCGR3A-mediated phagocytosi,,p(HGNC:ABL1),
Factors involved in megakaryocyte development and platelet productio,,p(HGNC:ABL1); p(HGNC:TP53); p(HGNC:JAK2); p(HGNC:GATA2); p(HGNC:GATA1),
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",,p(HGNC:ABL1),
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,,p(HGNC:POLD4); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLD2),
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,,p(HGNC:POLD4); p(HGNC:POLD3); p(HGNC:POLD1); p(HGNC:POLD2),
Downstream signal transductio,,p(HGNC:PDGFRB); p(HGNC:PDGFRA); p(HGNC:STAT5B); p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
Signaling by PDG,,p(HGNC:PDGFRB); p(HGNC:PDGFRA),
Platelet Aggregation (Plug Formation,,p(HGNC:MPL),
Class B/2 (Secretin family receptors,,p(HGNC:SMO),
Hedgehog 'off' stat,,p(HGNC:SMO),
BBSome-mediated cargo-targeting to ciliu,,p(HGNC:SMO),
Hedgehog 'on' stat,,p(HGNC:SMO); p(HGNC:RPS27A),
Activation of SM,,p(HGNC:SMO),
PKMTs methylate histone lysine,,p(HGNC:NSD1); p(HGNC:KMT2A); p(HGNC:SETD2); p(HGNC:EZH2),
SUMOylation of transcription cofactor,,p(HGNC:NPM1),
Deposition of new CENPA-containing nucleosomes at the centromer,,p(HGNC:NPM1),
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,,p(HGNC:TP53); p(HGNC:NPM1),
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiatio,,p(HGNC:NPM1),
SARS-CoV-1-host interaction,,p(HGNC:NPM1),
ALK mutants bind TKI,,p(HGNC:NPM1),
Signaling by ALK fusions and activated point mutant,,p(HGNC:TP53); p(HGNC:NPM1); p(HGNC:RPS27A),
Formation of WDR5-containing histone-modifying complexe,,p(HGNC:KMT2A),
Formation of Incision Complex in GG-NE,,p(HGNC:ERCC4); p(HGNC:RPS27A),
Signaling by SCF-KI,,p(HGNC:KIT); p(HGNC:JAK2); p(HGNC:PRKCA); p(HGNC:STAT5B); p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,,p(HGNC:KIT),
Dasatinib-resistant KIT mutant,,p(HGNC:KIT),
Imatinib-resistant KIT mutant,,p(HGNC:KIT),
KIT mutants bind TKI,,p(HGNC:KIT),
Masitinib-resistant KIT mutant,,p(HGNC:KIT),
Nilotinib-resistant KIT mutant,,p(HGNC:KIT),
Regorafenib-resistant KIT mutant,,p(HGNC:KIT),
Signaling by kinase domain mutants of KI,,p(HGNC:KIT),
Sunitinib-resistant KIT mutant,,p(HGNC:KIT),
Signaling by juxtamembrane domain KIT mutant,,p(HGNC:KIT),
Sorafenib-resistant KIT mutant,,p(HGNC:KIT),
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",,p(HGNC:KIT); p(HGNC:JAK2); p(HGNC:STAT5B); p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by extracellular domain mutants of KI,,p(HGNC:KIT),
Transcriptional and post-translational regulation of MITF-M expression and activit,,p(HGNC:KIT),
B-WICH complex positively regulates rRNA expressio,,p(HGNC:SF3B1),
EGFR Transactivation by Gastri,,p(HGNC:PRKCA); p(HGNC:KRAS); p(HGNC:NRAS),
Syndecan interaction,,p(HGNC:PRKCA),
Acetylcholine regulates insulin secretio,,p(HGNC:PRKCA),
Ca2+ pathwa,,p(HGNC:PRKCA),
ROBO receptors bind AKAP,,p(HGNC:PRKCA),
Frs2-mediated activatio,,p(HGNC:BRAF),
ARMS-mediated activatio,,p(HGNC:BRAF),
Signalling to p38 via RIT and RI,,p(HGNC:BRAF),
HDMs demethylate histone,,p(HGNC:KDM5A),
Chromatin modifications during the maternal to zygotic transition (MZT,,p(HGNC:KDM5A),
Transcriptional regulation of testis differentiatio,,p(HGNC:WT1),
Nephron developmen,,p(HGNC:WT1),
Regulation of TP53 Activity through Acetylatio,,p(HGNC:TP53); p(HGNC:PML),
Regulation of PTEN localizatio,,p(HGNC:PML); p(HGNC:RPS27A); p(HGNC:PTEN),
Transcriptional regulation of granulopoiesis. [P29590-,,p(HGNC:PML),
Neurophilin interactions with VEGF and VEGF,,p(HGNC:KDR),
Integrin cell surface interaction,,p(HGNC:KDR),
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,,p(HGNC:KDR); p(HGNC:ETV6),
Activation of NOXA and translocation to mitochondri,,p(HGNC:TP53),
Activation of PUMA and translocation to mitochondri,,p(HGNC:TP53),
Oxidative Stress Induced Senescenc,,p(HGNC:TP53); p(HGNC:RPS27A); p(HGNC:EZH2),
Formation of Senescence-Associated Heterochromatin Foci (SAHF,,p(HGNC:TP53),
Oncogene Induced Senescenc,,p(HGNC:TP53); p(HGNC:RPS27A),
SUMOylation of transcription factor,,p(HGNC:TP53),
Autodegradation of the E3 ubiquitin ligase COP,,p(HGNC:TP53); p(HGNC:RPS27A),
TP53 Regulates Metabolic Gene,,p(HGNC:TP53); p(HGNC:PTEN),
Ub-specific processing protease,,p(HGNC:TP53); p(HGNC:RPS27A); p(HGNC:PTEN),
Ovarian tumor domain protease,,p(HGNC:TP53); p(HGNC:RPS27A); p(HGNC:PTEN),
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,,p(HGNC:TP53),
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,,p(HGNC:TP53),
TP53 Regulates Transcription of Caspase Activators and Caspase,,p(HGNC:TP53),
TP53 Regulates Transcription of Death Receptors and Ligand,,p(HGNC:TP53),
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,,p(HGNC:TP53),
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,,p(HGNC:TP53),
Regulation of TP53 Expressio,,p(HGNC:TP53),
Regulation of TP53 Activity through Phosphorylatio,,p(HGNC:TP53); p(HGNC:RPS27A),
Regulation of TP53 Degradatio,,p(HGNC:TP53); p(HGNC:RPS27A),
Regulation of TP53 Activity through Association with Co-factor,,p(HGNC:TP53),
Regulation of TP53 Activity through Methylatio,,p(HGNC:TP53); p(HGNC:RPS27A),
PI5P Regulates TP53 Acetylatio,,p(HGNC:TP53),
G2/M DNA damage checkpoin,,p(HGNC:TP53),
G2/M Checkpoint,,p(HGNC:TP53); p(HGNC:RPS27A),
Stabilization of p5,,p(HGNC:TP53); p(HGNC:RPS27A),
Transcriptional activation of cell cycle inhibitor p2,,p(HGNC:TP53),
The role of GTSE1 in G2/M progression after G2 checkpoin,,p(HGNC:TP53); p(HGNC:RPS27A),
Transcriptional Regulation by VENT,,p(HGNC:TP53),
RUNX3 regulates CDKN1A transcriptio,,p(HGNC:TP53),
Regulation of PTEN gene transcriptio,,p(HGNC:TP53); p(HGNC:EZH2),
Loss of function of TP53 in cancer due to loss of tetramerization abilit,,p(HGNC:TP53),
Regulation of NF-kappa B signalin,,p(HGNC:TP53); p(HGNC:RPS27A),
Zygotic genome activation (ZGA,,p(HGNC:TP53),
Translesion Synthesis by POL,,p(HGNC:RPS27A),
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alph,,p(HGNC:RPS27A),
ER-Phagosome pathwa,,p(HGNC:RPS27A),
Downregulation of ERBB4 signalin,,p(HGNC:RPS27A),
Downregulation of ERBB2:ERBB3 signalin,,p(HGNC:RPS27A),
Budding and maturation of HIV virio,,p(HGNC:RPS27A),
NOD1/2 Signaling Pathwa,,p(HGNC:RPS27A),
"TICAM1, RIP1-mediated IKK complex recruitmen",,p(HGNC:RPS27A),
DDX58/IFIH1-mediated induction of interferon-alpha/bet,,p(HGNC:RPS27A),
APC/C:Cdc20 mediated degradation of Cyclin ,,p(HGNC:RPS27A),
Autodegradation of Cdh1 by Cdh1:APC/,,p(HGNC:RPS27A),
SCF-beta-TrCP mediated degradation of Emi,,p(HGNC:RPS27A),
APC/C:Cdc20 mediated degradation of Securi,,p(HGNC:RPS27A),
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G,,p(HGNC:RPS27A),
Cdc20:Phospho-APC/C mediated degradation of Cyclin ,,p(HGNC:RPS27A),
Membrane binding and targetting of GAG protein,,p(HGNC:RPS27A),
Assembly Of The HIV Virio,,p(HGNC:RPS27A),
APC-Cdc20 mediated degradation of Nek2,,p(HGNC:RPS27A),
Vpu mediated degradation of CD,,p(HGNC:RPS27A),
Vif-mediated degradation of APOBEC3,,p(HGNC:RPS27A),
SCF(Skp2)-mediated degradation of p27/p2,,p(HGNC:RPS27A),
Degradation of beta-catenin by the destruction comple,,p(HGNC:RPS27A),
TCF dependent signaling in response to WN,,p(HGNC:RPS27A),
NRIF signals cell death from the nucleu,,p(HGNC:RPS27A),
NF-kB is activated and signals surviva,,p(HGNC:RPS27A),
Regulation of activated PAK-2p34 by proteasome mediated degradatio,,p(HGNC:RPS27A),
NOTCH1 Intracellular Domain Regulates Transcriptio,,p(HGNC:RPS27A),
Activated NOTCH1 Transmits Signal to the Nucleu,,p(HGNC:RPS27A),
Downregulation of TGF-beta receptor signalin,,p(HGNC:RPS27A),
Downregulation of SMAD2/3:SMAD4 transcriptional activit,,p(HGNC:RPS27A),
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptio,,p(HGNC:RPS27A),
Senescence-Associated Secretory Phenotype (SASP,,p(HGNC:RPS27A),
Regulation of PLK1 Activity at G2/M Transitio,,p(HGNC:RPS27A),
Constitutive Signaling by NOTCH1 PEST Domain Mutant,,p(HGNC:RPS27A),
Constitutive Signaling by NOTCH1 HD Domain Mutant,,p(HGNC:RPS27A),
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutant,,p(HGNC:RPS27A),
NOTCH2 Activation and Transmission of Signal to the Nucleu,,p(HGNC:RPS27A),
Regulation of innate immune responses to cytosolic DN,,p(HGNC:RPS27A); p(HGNC:DDX41),
Glycogen synthesi,,p(HGNC:RPS27A),
Deactivation of the beta-catenin transactivating comple,,p(HGNC:RPS27A),
Myoclonic epilepsy of Lafor,,p(HGNC:RPS27A),
ABC-family proteins mediated transpor,,p(HGNC:RPS27A),
Circadian Cloc,,p(HGNC:RPS27A),
TAK1-dependent IKK and NF-kappa-B activatio,,p(HGNC:RPS27A),
activated TAK1 mediates p38 MAPK activatio,,p(HGNC:RPS27A),
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK,,p(HGNC:RPS27A),
AUF1 (hnRNP D0) binds and destabilizes mRN,,p(HGNC:RPS27A),
Asymmetric localization of PCP protein,,p(HGNC:RPS27A),
Degradation of AXI,,p(HGNC:RPS27A),
Degradation of DV,,p(HGNC:RPS27A),
Regulation of FZD by ubiquitinatio,,p(HGNC:RPS27A),
PINK1-PRKN Mediated Mitophag,,p(HGNC:RPS27A),
N-glycan trimming in the ER and Calnexin/Calreticulin cycl,,p(HGNC:RPS27A),
Regulation of TNFR1 signalin,,p(HGNC:RPS27A),
TNFR1-induced NF-kappa-B signaling pathwa,,p(HGNC:RPS27A),
Hedgehog ligand biogenesi,,p(HGNC:RPS27A),
Hh mutants are degraded by ERA,,p(HGNC:RPS27A),
Dectin-1 mediated noncanonical NF-kB signalin,,p(HGNC:RPS27A),
Degradation of GLI1 by the proteasom,,p(HGNC:RPS27A),
Degradation of GLI2 by the proteasom,,p(HGNC:RPS27A),
GLI3 is processed to GLI3R by the proteasom,,p(HGNC:RPS27A),
TNFR2 non-canonical NF-kB pathwa,,p(HGNC:RPS27A),
Regulation of necroptotic cell deat,,p(HGNC:RPS27A),
NIK-->noncanonical NF-kB signalin,,p(HGNC:RPS27A),
Defective CFTR causes cystic fibrosi,,p(HGNC:RPS27A),
MAP3K8 (TPL2)-dependent MAPK1/3 activatio,,p(HGNC:RPS27A),
MAPK6/MAPK4 signalin,,p(HGNC:RPS27A),
Josephin domain DUB,,p(HGNC:RPS27A),
Metalloprotease DUB,,p(HGNC:RPS27A),
Processing of DNA double-strand break end,,p(HGNC:RPS27A),
DNA Damage Recognition in GG-NE,,p(HGNC:RPS27A),
Formation of TC-NER Pre-Incision Comple,,p(HGNC:RPS27A),
Transcription-Coupled Nucleotide Excision Repair (TC-NER,,p(HGNC:RPS27A),
Assembly of the pre-replicative comple,,p(HGNC:RPS27A),
Orc1 removal from chromati,,p(HGNC:RPS27A),
CDK-mediated phosphorylation and removal of Cdc,,p(HGNC:RPS27A),
Ubiquitin Mediated Degradation of Phosphorylated Cdc25,,p(HGNC:RPS27A),
Ubiquitin-dependent degradation of Cyclin ,,p(HGNC:RPS27A),
FBXL7 down-regulates AURKA during mitotic entry and in early mitosi,,p(HGNC:RPS27A),
Downregulation of ERBB2 signalin,,p(HGNC:RPS27A),
VLDLR internalisation and degradatio,,p(HGNC:RPS27A),
E3 ubiquitin ligases ubiquitinate target protein,,p(HGNC:RPS27A),
InlA-mediated entry of Listeria monocytogenes into host cell,,p(HGNC:RPS27A),
Regulation of RUNX2 expression and activit,,p(HGNC:RPS27A),
Regulation of RUNX3 expression and activit,,p(HGNC:RPS27A),
Regulation of PTEN stability and activit,,p(HGNC:RPS27A); p(HGNC:PTEN),
Neddylatio,,p(HGNC:RPS27A); p(HGNC:PALB2),
ER Quality Control Compartment (ERQC,,p(HGNC:RPS27A),
NOTCH3 Activation and Transmission of Signal to the Nucleu,,p(HGNC:RPS27A),
TICAM1-dependent activation of IRF3/IRF,,p(HGNC:RPS27A),
"TICAM1,TRAF6-dependent induction of TAK1 comple",,p(HGNC:RPS27A),
Interleukin-1 signalin,,p(HGNC:RPS27A),
Interferon alpha/beta signalin,,p(HGNC:RPS27A); p(HGNC:PTPN11),
Endosomal Sorting Complex Required For Transport (ESCRT,,p(HGNC:RPS27A),
Iron uptake and transpor,,p(HGNC:RPS27A),
Negative regulators of DDX58/IFIH1 signalin,,p(HGNC:RPS27A),
"Activation of IRF3, IRF7 mediated by TBK1, IKKEpsilon (IKBKE",,p(HGNC:RPS27A); p(HGNC:PTPN11),
IRAK1 recruits IKK comple,,p(HGNC:RPS27A),
IKK complex recruitment mediated by RIP,,p(HGNC:RPS27A),
IRAK2 mediated activation of TAK1 comple,,p(HGNC:RPS27A),
TRAF6-mediated induction of TAK1 complex within TLR4 comple,,p(HGNC:RPS27A),
Negative regulation of NOTCH4 signalin,,p(HGNC:RPS27A),
Chaperone Mediated Autophag,,p(HGNC:RPS27A),
Late endosomal microautophag,,p(HGNC:RPS27A),
Prevention of phagosomal-lysosomal fusio,,p(HGNC:RPS27A),
Modulation by Mtb of host immune syste,,p(HGNC:RPS27A),
Alpha-protein kinase 1 signaling pathwa,,p(HGNC:RPS27A),
Aggrephag,,p(HGNC:RPS27A),
Pexophag,,p(HGNC:RPS27A),
Maturation of protein ,,p(HGNC:RPS27A),
Regulation of BACH1 activit,,p(HGNC:RPS27A),
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signalin,,p(HGNC:RPS27A),
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulatio,,p(HGNC:RPS27A),
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulatio,,p(HGNC:RPS27A),
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L,,p(HGNC:RPS27A),
Amyloid fiber formatio,,p(HGNC:RPS27A),
"Regulation of TBK1, IKKEpsilon (IKBKE)-mediated activation of IRF3, IRF",,p(HGNC:RPS27A),
"Regulation of TBK1, IKKEpsilon-mediated activation of IRF3, IRF7 upon TLR3 ligatio",,p(HGNC:RPS27A),
Antigen processing: Ubiquitination & Proteasome degradatio,,p(HGNC:RPS27A),
Evasion by RSV of host interferon response,,p(HGNC:RPS27A),
Regulation of pyruvate metabolis,,p(HGNC:RPS27A),
"TET1,2,3 and TDG demethylate DN",,p(HGNC:TET2),
Specification of primordial germ cell,,p(HGNC:TET2),
Cytosolic iron-sulfur cluster assembl,,p(HGNC:RTEL1); p(HGNC:POLD1),
Transcriptional activation of mitochondrial biogenesi,,p(HGNC:IDH2),
Citric acid cycle (TCA cycle,,p(HGNC:IDH2),
Mitochondrial protein degradatio,,p(HGNC:IDH2),
Maturation of TCA enzymes and regulation of TCA cycl,,p(HGNC:IDH2),
G1/S-Specific Transcriptio,,p(HGNC:POLA1),
Prolactin receptor signalin,,p(HGNC:JAK2); p(HGNC:STAT5B); p(HGNC:PTPN11),
Interleukin-7 signalin,,p(HGNC:STAT5B),
Signaling by cytosolic FGFR1 fusion mutant,,p(HGNC:STAT5B); p(HGNC:BCR),
Signaling by Lepti,,p(HGNC:JAK2); p(HGNC:STAT5B); p(HGNC:PTPN11),
Interleukin-20 family signalin,,p(HGNC:JAK2); p(HGNC:STAT5B); p(HGNC:PTPN11),
Interleukin-15 signalin,,p(HGNC:STAT5B),
Interleukin-9 signalin,,p(HGNC:STAT5B),
Interleukin-2 signalin,,p(HGNC:STAT5B),
Interleukin-21 signalin,,p(HGNC:STAT5B),
Erythropoietin activates STAT,,p(HGNC:JAK2); p(HGNC:STAT5B),
Signaling by FLT3 fusion protein,,p(HGNC:STAT5B); p(HGNC:KRAS); p(HGNC:ETV6); p(HGNC:NRAS),
Growth hormone receptor signalin,,p(HGNC:JAK2); p(HGNC:STAT5B),
SOS-mediated signallin,,p(HGNC:KRAS); p(HGNC:NRAS),
Activation of RAS in B cell,,p(HGNC:KRAS); p(HGNC:NRAS),
SHC1 events in ERBB4 signalin,,p(HGNC:KRAS); p(HGNC:NRAS),
Signalling to RA,,p(HGNC:KRAS); p(HGNC:NRAS),
p38MAPK event,,p(HGNC:KRAS); p(HGNC:NRAS),
GRB2 events in EGFR signalin,,p(HGNC:KRAS); p(HGNC:NRAS),
SHC1 events in EGFR signalin,,p(HGNC:KRAS); p(HGNC:NRAS),
GRB2 events in ERBB2 signalin,,p(HGNC:KRAS); p(HGNC:NRAS),
Tie2 Signalin,,p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
DAP12 signalin,,p(HGNC:KRAS); p(HGNC:NRAS),
SHC-related events triggered by IGF1,,p(HGNC:KRAS); p(HGNC:NRAS),
FCERI mediated MAPK activatio,,p(HGNC:KRAS); p(HGNC:NRAS),
NCAM signaling for neurite out-growt,,p(HGNC:KRAS); p(HGNC:NRAS),
Ca2+ pathway. [P01116-,,p(HGNC:KRAS),
Ras activation upon Ca2+ influx through NMDA recepto,,p(HGNC:KRAS); p(HGNC:NRAS),
SHC-mediated cascade:FGFR,,p(HGNC:KRAS); p(HGNC:NRAS),
FRS-mediated FGFR1 signalin,,p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
FRS-mediated FGFR2 signalin,,p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
FRS-mediated FGFR3 signalin,,p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
FRS-mediated FGFR4 signalin,,p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
Signaling by FGFR2 in diseas,,p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by FGFR4 in diseas,,p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by FGFR1 in diseas,,p(HGNC:KRAS); p(HGNC:BCR); p(HGNC:NRAS),
Signaling by FGFR3 in diseas,,p(HGNC:KRAS); p(HGNC:NRAS),
Insulin receptor signalling cascad,,p(HGNC:KRAS); p(HGNC:NRAS),
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinase",,p(HGNC:KRAS); p(HGNC:NRAS),
MET activates RAS signalin,,p(HGNC:KRAS); p(HGNC:NRAS),
Activated NTRK2 signals through RA,,p(HGNC:KRAS); p(HGNC:NRAS),
Erythropoietin activates RA,,p(HGNC:JAK2); p(HGNC:KRAS); p(HGNC:NRAS),
Activated NTRK2 signals through FRS2 and FRS,,p(HGNC:KRAS); p(HGNC:PTPN11); p(HGNC:NRAS),
Activated NTRK3 signals through RA,,p(HGNC:KRAS); p(HGNC:NRAS),
Constitutive Signaling by Overexpressed ERBB,,p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by ERBB2 KD Mutant,,p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by ERBB2 ECD mutant,,p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by ERBB2 TMD/JMD mutant,,p(HGNC:KRAS); p(HGNC:NRAS),
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",,p(HGNC:PDGFRA); p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by PDGFRA extracellular domain mutant,,p(HGNC:PDGFRA); p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by RAS GAP mutant,,p(HGNC:KRAS); p(HGNC:NRAS),
Signaling by RAS GTPase mutant,,p(HGNC:KRAS); p(HGNC:NRAS),
STING mediated induction of host immune response,,p(HGNC:DDX41),
IRF3-mediated induction of type I IF,,p(HGNC:DDX41),
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cel,,p(HGNC:CD33),
Synthesis of PIPs at the plasma membran,,p(HGNC:PTEN),
Synthesis of IP3 and IP4 in the cytoso,,p(HGNC:PTEN),
Negative regulation of the PI3K/AKT networ,,p(HGNC:PTEN),
PTEN Loss of Function in Cance,,p(HGNC:PTEN),
Regulation of PTEN mRNA translatio,,p(HGNC:PTEN),
Transcriptional Regulation by MECP,,p(HGNC:PTEN),
MAPK3 (ERK1) activatio,,p(HGNC:JAK2); p(HGNC:PTPN11),
MAPK1 (ERK2) activatio,,p(HGNC:JAK2); p(HGNC:PTPN11),
GAB1 signalosom,,p(HGNC:PTPN11),
PECAM1 interaction,,p(HGNC:PTPN11),
Co-inhibition by CTLA,,p(HGNC:PTPN11),
Co-inhibition by PD-,,p(HGNC:PTPN11),
Signal regulatory protein family interaction,,p(HGNC:PTPN11),
Netrin mediated repulsion signal,,p(HGNC:PTPN11),
Platelet sensitization by LD,,p(HGNC:PTPN11),
PI-3K cascade:FGFR,,p(HGNC:PTPN11),
Regulation of IFNG signalin,,p(HGNC:JAK2); p(HGNC:PTPN11),
MET activates PTPN1,,p(HGNC:PTPN11),
Interleukin-37 signalin,,p(HGNC:PTPN11),
Regulation of IFNA/IFNB signalin,,p(HGNC:PTPN11),
Co-inhibition by BTL,,p(HGNC:PTPN11),
RHOA GTPase cycl,,p(HGNC:BCR),
RHOB GTPase cycl,,p(HGNC:BCR),
RHOC GTPase cycl,,p(HGNC:BCR),
CDC42 GTPase cycl,,p(HGNC:BCR),
RAC1 GTPase cycl,,p(HGNC:BCR),
RAC2 GTPase cycl,,p(HGNC:BCR),
RAC3 GTPase cycl,,p(HGNC:BCR),
Transcriptional Regulation by E2F,,p(HGNC:EZH2),
Displacement of DNA glycosylase by APEX,,p(HGNC:MBD4),
IL-6-type cytokine receptor ligand interaction,,p(HGNC:JAK2),
Interleukin-35 Signallin,,p(HGNC:JAK2),
Signaling by Erythropoieti,,p(HGNC:JAK2),
Interleukin-12 signalin,,p(HGNC:JAK2),
Interleukin-23 signalin,,p(HGNC:JAK2),
Interleukin-27 signalin,,p(HGNC:JAK2),
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,,p(HGNC:JAK2),
Erythropoietin activates Phospholipase C gamma (PLCG,,p(HGNC:JAK2),
Potential therapeutics for SAR,,p(HGNC:JAK2),
Imatinib-resistant PDGFR mutant,,p(HGNC:PDGFRA),
Sunitinib-resistant PDGFR mutant,,p(HGNC:PDGFRA),
Regorafenib-resistant PDGFR mutant,,p(HGNC:PDGFRA),
Sorafenib-resistant PDGFR mutant,,p(HGNC:PDGFRA),
PDGFR mutants bind TKI,,p(HGNC:PDGFRA),
